The recent decline in Foghorn Therapeutics' stock was attributed to the discontinuation of another of its products, FHD-286. However, the analysts emphasized that this event does not impact their ...

B. Riley issued their Q1 2025 earnings estimates for Customers Bancorp in a research note issued to investors on Monday, ...

B. Riley Financial Inc (NASDAQ:RILY). has paused the payment of dividends on two of its preferred stock offerings. The ...

Learn about the latest financial trends and strategies in our comprehensive article written by a financial expert.

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...

B. Riley analyst Kyle Bauser raised the firm’s price target on ClearPoint Neuro (CLPT) to $20 from $15 and keeps a Buy rating ...

Analysts at B. Riley reduced their FY2024 earnings estimates for shares of Ladder Capital in a research report issued to clients and investors on Monday, January 27th. B. Riley analyst R. Binner now ...

Chairman Bryant Riley has put a priority on paying down debt as his firm seeks to recover from a string of losses.

B. Riley analyst Zach Cummins downgraded Logility (LGTY) to Neutral from Buy with a $14.30 price target after Aptean, Insight Partners, ...